ArticleBreast cancer (Tokyo, Japan)2025

Optimal patient population for adjuvant S-1 therapy in hormone receptor-positive, HER2-negative early breast cancer.

Ayaka Isogai et al.PubMed ↗Publisher ↗

No numbers read from the abstract.